Statement of Changes in Beneficial Ownership (4)
June 23 2020 - 4:47PM
Edgar (US Regulatory)
FORM 4
[X]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Ferrante Karen Jean |
2. Issuer Name and Ticker or Trading Symbol
PROGENICS PHARMACEUTICALS INC
[
PGNX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
|
|
(Last)
(First)
(Middle)
ONE WORLD TRADE CENTER, 47TH FLOOR, SUITE J |
3. Date of Earliest Transaction
(MM/DD/YYYY)
6/19/2020 |
|
(Street)
NEW YORK, NY 10007
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (Right to Buy) | $4.50 | 6/19/2020 | | D | | | 40000 | (1) | 1/28/2024 | Common Stock | 40000 | (1) | 0 | D | |
| Stock Option (Right to Buy) | $4.47 | 6/19/2020 | | D | | | 20000 | (1) | 6/16/2024 | Common Stock | 20000 | (1) | 0 | D | |
| Stock Option (Right to Buy) | $6.72 | 6/19/2020 | | D | | | 20000 | (1) | 6/9/2025 | Common Stock | 20000 | (1) | 0 | D | |
| Stock Option (Right to Buy) | $4.89 | 6/19/2020 | | D | | | 20000 | (1) | 6/7/2026 | Common Stock | 20000 | (1) | 0 | D | |
| Stock Option (Right to Buy) | $6.95 | 6/19/2020 | | D | | | 20000 | (1) | 6/13/2027 | Common Stock | 20000 | (1) | 0 | D | |
| Stock Option (Right to Buy) | $8.99 | 6/19/2020 | | D | | | 25000 | (1) | 6/12/2028 | Common Stock | 25000 | (1) | 0 | D | |
| Stock Option (Right to Buy) | $5.74 | 6/19/2020 | | D | | | 25000 | (1) | 7/11/2029 | Common Stock | 25000 | (1) | 0 | D | |
| Explanation of Responses: |
| (1) | On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Ferrante Karen Jean
ONE WORLD TRADE CENTER
47TH FLOOR, SUITE J
NEW YORK, NY 10007 | X |
|
|
|
Signatures
|
| /s/ Karen Ferrante | | 6/23/2020 |
| **Signature of Reporting Person | Date |
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Dec 2023 to Dec 2024
